Cargando…

A mutant of phosphomannomutase1 retains full enzymatic activity, but is not activated by IMP: Possible implications for the disease PMM2-CDG

The most frequent disorder of glycosylation, PMM2-CDG, is caused by a deficiency of phosphomannomutase activity. In humans two paralogous enzymes exist, both of them require mannose 1,6-bis-phosphate or glucose 1,6-bis-phosphate as activators, but only phospho-mannomutase1 hydrolyzes bis-phosphate h...

Descripción completa

Detalles Bibliográficos
Autores principales: Citro, Valentina, Cimmaruta, Chiara, Liguori, Ludovica, Viscido, Gaetano, Cubellis, Maria Vittoria, Andreotti, Giuseppina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5736207/
https://www.ncbi.nlm.nih.gov/pubmed/29261720
http://dx.doi.org/10.1371/journal.pone.0189629
_version_ 1783287337381265408
author Citro, Valentina
Cimmaruta, Chiara
Liguori, Ludovica
Viscido, Gaetano
Cubellis, Maria Vittoria
Andreotti, Giuseppina
author_facet Citro, Valentina
Cimmaruta, Chiara
Liguori, Ludovica
Viscido, Gaetano
Cubellis, Maria Vittoria
Andreotti, Giuseppina
author_sort Citro, Valentina
collection PubMed
description The most frequent disorder of glycosylation, PMM2-CDG, is caused by a deficiency of phosphomannomutase activity. In humans two paralogous enzymes exist, both of them require mannose 1,6-bis-phosphate or glucose 1,6-bis-phosphate as activators, but only phospho-mannomutase1 hydrolyzes bis-phosphate hexoses. Mutations in the gene encoding phosphomannomutase2 are responsible for PMM2-CDG. Although not directly causative of the disease, the role of the paralogous enzyme in the disease should be clarified. Phosphomannomutase1 could have a beneficial effect, contributing to mannose 6-phosphate isomerization, or a detrimental effect, hydrolyzing the bis-phosphate hexose activator. A pivotal role in regulating mannose-1phosphate production and ultimately protein glycosylation might be played by inosine monophosphate that enhances the phosphatase activity of phosphomannomutase1. In this paper we analyzed human phosphomannomutases by conventional enzymatic assays as well as by novel techniques such as (31)P-NMR and thermal shift assay. We characterized a triple mutant of phospomannomutase1 that retains mutase and phosphatase activity, but is unable to bind inosine monophosphate.
format Online
Article
Text
id pubmed-5736207
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-57362072017-12-22 A mutant of phosphomannomutase1 retains full enzymatic activity, but is not activated by IMP: Possible implications for the disease PMM2-CDG Citro, Valentina Cimmaruta, Chiara Liguori, Ludovica Viscido, Gaetano Cubellis, Maria Vittoria Andreotti, Giuseppina PLoS One Research Article The most frequent disorder of glycosylation, PMM2-CDG, is caused by a deficiency of phosphomannomutase activity. In humans two paralogous enzymes exist, both of them require mannose 1,6-bis-phosphate or glucose 1,6-bis-phosphate as activators, but only phospho-mannomutase1 hydrolyzes bis-phosphate hexoses. Mutations in the gene encoding phosphomannomutase2 are responsible for PMM2-CDG. Although not directly causative of the disease, the role of the paralogous enzyme in the disease should be clarified. Phosphomannomutase1 could have a beneficial effect, contributing to mannose 6-phosphate isomerization, or a detrimental effect, hydrolyzing the bis-phosphate hexose activator. A pivotal role in regulating mannose-1phosphate production and ultimately protein glycosylation might be played by inosine monophosphate that enhances the phosphatase activity of phosphomannomutase1. In this paper we analyzed human phosphomannomutases by conventional enzymatic assays as well as by novel techniques such as (31)P-NMR and thermal shift assay. We characterized a triple mutant of phospomannomutase1 that retains mutase and phosphatase activity, but is unable to bind inosine monophosphate. Public Library of Science 2017-12-19 /pmc/articles/PMC5736207/ /pubmed/29261720 http://dx.doi.org/10.1371/journal.pone.0189629 Text en © 2017 Citro et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Citro, Valentina
Cimmaruta, Chiara
Liguori, Ludovica
Viscido, Gaetano
Cubellis, Maria Vittoria
Andreotti, Giuseppina
A mutant of phosphomannomutase1 retains full enzymatic activity, but is not activated by IMP: Possible implications for the disease PMM2-CDG
title A mutant of phosphomannomutase1 retains full enzymatic activity, but is not activated by IMP: Possible implications for the disease PMM2-CDG
title_full A mutant of phosphomannomutase1 retains full enzymatic activity, but is not activated by IMP: Possible implications for the disease PMM2-CDG
title_fullStr A mutant of phosphomannomutase1 retains full enzymatic activity, but is not activated by IMP: Possible implications for the disease PMM2-CDG
title_full_unstemmed A mutant of phosphomannomutase1 retains full enzymatic activity, but is not activated by IMP: Possible implications for the disease PMM2-CDG
title_short A mutant of phosphomannomutase1 retains full enzymatic activity, but is not activated by IMP: Possible implications for the disease PMM2-CDG
title_sort mutant of phosphomannomutase1 retains full enzymatic activity, but is not activated by imp: possible implications for the disease pmm2-cdg
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5736207/
https://www.ncbi.nlm.nih.gov/pubmed/29261720
http://dx.doi.org/10.1371/journal.pone.0189629
work_keys_str_mv AT citrovalentina amutantofphosphomannomutase1retainsfullenzymaticactivitybutisnotactivatedbyimppossibleimplicationsforthediseasepmm2cdg
AT cimmarutachiara amutantofphosphomannomutase1retainsfullenzymaticactivitybutisnotactivatedbyimppossibleimplicationsforthediseasepmm2cdg
AT liguoriludovica amutantofphosphomannomutase1retainsfullenzymaticactivitybutisnotactivatedbyimppossibleimplicationsforthediseasepmm2cdg
AT viscidogaetano amutantofphosphomannomutase1retainsfullenzymaticactivitybutisnotactivatedbyimppossibleimplicationsforthediseasepmm2cdg
AT cubellismariavittoria amutantofphosphomannomutase1retainsfullenzymaticactivitybutisnotactivatedbyimppossibleimplicationsforthediseasepmm2cdg
AT andreottigiuseppina amutantofphosphomannomutase1retainsfullenzymaticactivitybutisnotactivatedbyimppossibleimplicationsforthediseasepmm2cdg
AT citrovalentina mutantofphosphomannomutase1retainsfullenzymaticactivitybutisnotactivatedbyimppossibleimplicationsforthediseasepmm2cdg
AT cimmarutachiara mutantofphosphomannomutase1retainsfullenzymaticactivitybutisnotactivatedbyimppossibleimplicationsforthediseasepmm2cdg
AT liguoriludovica mutantofphosphomannomutase1retainsfullenzymaticactivitybutisnotactivatedbyimppossibleimplicationsforthediseasepmm2cdg
AT viscidogaetano mutantofphosphomannomutase1retainsfullenzymaticactivitybutisnotactivatedbyimppossibleimplicationsforthediseasepmm2cdg
AT cubellismariavittoria mutantofphosphomannomutase1retainsfullenzymaticactivitybutisnotactivatedbyimppossibleimplicationsforthediseasepmm2cdg
AT andreottigiuseppina mutantofphosphomannomutase1retainsfullenzymaticactivitybutisnotactivatedbyimppossibleimplicationsforthediseasepmm2cdg